Hofman Véronique, Gaziello Marie-Clotilde, Bonnetaud Christelle, Ilie Marius, Mauro Virginie, Long Elodie, Selva Eric, Gavric-Tanga Virginie, Lassalle Sandra, Butori Catherine, Papin-Michaud Caroline, Lerda Nathalie, Bordone Olivier, Coelle Céline, Sabourin Jean-Christophe, Chabannon Christian, Hofman Paul
Tumorothèque-centre de ressources biologiques, université de Nice Sophia-Antipolis, hôpital Pasteur, CHU, Nice, France.
Ann Pathol. 2012 Apr;32(2):91-101. doi: 10.1016/j.annpat.2012.02.002. Epub 2012 Mar 28.
The biobanking area is highly complex, and its complexity is increasing along with its growth and demand. Due to the advancements in genetic research, stem cell research and regenerative medicine, biobanking has become ever more important and plays a key role in biomedical research. The robustness and the reproducibility of research results depend greatly on the quality and on the number of the samples used, and thus on the expertise of biobanks having supplied these samples. Undoubtedly, the recognition of a research biobank depends on the impact of the research projects conducted with samples obtained from tumour bank(s), but also on many other criteria. It thus seems important to determine a number of indicators within a biobank to estimate objective criteria for the performance of these structures. These indicators can allow to make some strategic decisions knowing that biobanks are expensive structures to maintain in the present hospital context. The use of these indicators could also contribute to the elaboration of an "biobank impact factor of" or so called "bioresource research impact factor" (BRIF). We describe here four major categories of indicators (quality, activity, scientific production, visibility), which seem to be useful for the evaluation of a biobank by making a proposition of allocation of coefficients for the various considered items.
生物样本库领域极为复杂，且随着其发展和需求的增长，复杂性还在不断增加。由于基因研究、干细胞研究和再生医学的进步，生物样本库变得愈发重要，并在生物医学研究中发挥着关键作用。研究结果的稳健性和可重复性在很大程度上取决于所使用样本的质量和数量，进而取决于提供这些样本的生物样本库的专业水平。毫无疑问，一个研究性生物样本库的认可度不仅取决于利用从肿瘤样本库获取的样本开展的研究项目所产生的影响，还取决于许多其他标准。因此，在生物样本库内部确定一些指标，以评估这些机构运行的客观标准，似乎很重要。鉴于在当前医院环境下维持生物样本库成本高昂，这些指标有助于做出一些战略决策。这些指标的使用还可能有助于制定一个“生物样本库影响因子”或所谓的“生物资源研究影响因子”（BRIF）。我们在此描述四类主要指标（质量、活动、科研产出、知名度），通过对各项指标进行系数分配，这些指标似乎对评估生物样本库很有用。
